Harry J. Leonhardt's most recent trade in Poseida Therapeutics Inc was a trade of 223,640 Common Stock done . Disclosure was reported to the exchange on Jan. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | 08 Jan 2025 | 223,640 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 160,385 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 137,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 125,283 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 111,700 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 72,568 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 111,700 | 111,700 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 80,743 | 230,946 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 01 Mar 2024 | 16,306 | 214,640 | - | 4.1 | 67,344 | Common Stock |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 125,283 | 125,283 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 92,772 | 148,526 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.35 per share. | 01 Mar 2023 | 4,323 | 144,203 | - | 5.3 | 23,128 | Common Stock |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 72,568 | 72,568 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 50,000 | 50,000 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Harry J. Leonhardt | GC & Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 137,000 | 137,000 | - | - | Employee Stock Option (Right to Buy) |